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DEVELOPING HOSPICE DRUG FORMULARY USING MULTI-
ATTRIBUTE UTILITY THEORY (MAUT) METHODOLOGY
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1Auburn University, Auburn, AL, USA, 2Hospice of East Alabama
Medical Center, Auburn, AL, USA
OBJECTIVE: With the increasing costs of providing pharma-
ceutical care, hospices in the U.S, are burdened with the high
costs of providing optimum healthcare. There is a need to
implement cost-containment strategies such as drug formulary at
hospices that will aid in curbing pharmacy-related costs. While
most hospices do not have a formulary, there are some that have
a preferred drug list of most commonly used drugs, however,
they lack appropriate methodology for the purpose of including
particular drug(s) on the list. To develop rational hospice drug
formulary based on scientiﬁc methodology. METHODS: This
study was conducted at a hospice center located in the rural
township of Alabama State. Multi-Attribute Utility Theory
(MAUT) methodology was employed to develop a rational
hospice drug formulary. MAUT is a systematic identiﬁcation and
analysis method that facilitates the P&T committee in selecting
appropriate drugs on the basis of assessing important drug
attributes such as efﬁcacy, safety, cost, and dosage-form related
parameters. For each therapeutic drug class, members of the
P&T committee at the center ranked and weighted their prefer-
ences for different drug attributes that were considered most
important for ﬁnal drug selection process. The preference values
were combined in a mathematical formula with the literature
values that were obtained through comprehensive and system-
atic literature review process to yield total utility score values for
individual drugs. Within each therapeutic class, ﬁnal decisions to
include particular drug on the formulary were made on the basis
of total utility scores i.e. those drugs with highest total utility
scores were selected for the formulary. RESULTS: The P&T com-
mittee at the hospice center successfully developed their drug for-
mulary using MAUT methodology. CONCLUSIONS: The
methods described and employed in this study can be used by
P&T committees at other hospices for developing drug formu-
laries at their respective centers.
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SINGLE SOURCE COST ESTIMATES FOR EVENTS ACROSS
VARIOUS CONDITIONS REQUIRING THROMBOEMBOLIC
PROPHYLAXIS AND TREATMENT
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OBJECTIVES: Many studies have provided cost estimates for
thromboembolic events and bleeding episodes in several of the
populations for which thromboembolic prophylaxis is recom-
mended. However, these studies have focused on single indica-
tions and used various methodologies to generate the cost
estimates. This analysis assessed the relative costs of each event
type across several thromboembolic prophylaxis or treatment
indications from a single data source. METHODS: This was a
retrospective analysis of inpatient data from >500 US hospitals.
Patients hospitalized for occurrence of a deep vein thrombosis
(DVT) or pulmonary embolism (PE), orthopedic surgery (hip
fracture, knee or hip replacement), abdominal surgery, or acute
coronary syndrome (ACS) between January 2003 and March
2005 were eligible for study inclusion. Patients <18yrs of age
were excluded. Eligible patients were divided into eight outcomes
groups based on the presence of the secondary diagnosis ICD-9
codes upon hospital discharge: uncomplicated, DVT, PE, both
DVT and PE (DVT/PE), thrombocytopenia (TCP), major bleed
(MB), minor bleed (mB), and multiple events (multi). Billing ﬁles
were used to determine the average total cost per hospitalization
for each cohort. RESULTS: Sample sizes: orthopedic = 154,321;
abdominal = 237,836; TxDVT/PE = 23,698; ACS = 343,703.
The cost of an uncomplicated visit served as the baseline cost for
that cohort: orthopedic = $13,609; abdominal = $15,989;
TxDVT/PE = $5681; ACS = $13,133. Incremental costs for
events were highest in the abdominal cohort (mB = $7907 to
multi = $48,401), followed by ACS (PE = $4051 to multi =
$27,409), orthopedic (mB = $3480 to multi = $17,471), and
TxDVT/PE (PE = $2267 to MB = $13,969). Multi and MB were
the highest cost events in all cohorts except orthopedic surgery
where multi and DVT/PE were the most costly. CONCLU-
SIONS: Point estimates for average costs for events associated
with VTE prophylaxis and treatment differ across conditions.
The most costly events are typically multi and MB. Events in the
abdominal surgery population lead to the higher cost increases
compared to other cohorts.
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RATE OF LOW-DENSITY LIPOPROTEIN (LDL) GOAL
ATTAINMENT WITH LIPID LOWERING THERAPIES AT A LIPID
CLINIC IN A PUBLIC HOSPITAL OF HONG KONG—POSSIBLE
ROLE OF A CLINICAL PHARMACY SERVICE
Lee VWY, Chung JS, Ng SL,Tomlinson B, Lee KK
The Chinese University of Hong Kong, Shatin, Hong Kong, China
OBJECTIVES: Coronary heart disease (CHD) is the second most
important disease leading to mortalities in Hong Kong. In
persons with established CHD, evidence has demonstrated that
low-density lipoprotein (LDL) lowering therapy has resulted in
reduced mortality and cardiovascular events. We evaluated the
rate of LDL goal attainment of hyperlipidaemic patients at a
public hospital in Hong Kong. METHODS: This is a prospec-
tive observational trial conducted at the Lipid Clinic of the Prince
of Wales Hospital in Hong Kong. Chinese patients aged 18 years
or above with history of hyperlipidaemia and CHD are included.
Statin therapy must be prescribed for at least 3 months after
initial hospitalization. Treatment patterns were determined by
studying the dosages, titration, switch or discontinuation of
statin therapy. A LDL level of 2.6mmol/L was considered satis-
factory. RESULTS: Thirty-nine patients were recruited. The
mean age of patients was 61 ± 13 years old. Nearly 80% of
patients had CHD risk factors and 40% of patients have CHD
and CHD risk equivalents. In patients with comorbidities of
hypertension and diabetes, nearly 50% and 60% of patients had
unsatisfactory blood pressure control and unsatisfactory haemo-
globin A1C levels respectively. The mean baseline LDL was 2.97
± 0.99mmol/L. Only 41% of patients were at LDL goal. Lipid
lowering drugs used included rosuvastatin (21.4%), simvastatin
(26.2%), atorvastatin (19.0%), ﬂuvastatin (2.4%), ezetimibe
(7.1%), cholestyramine (7.1%), gemfribrozil (2.4%) and acipi-
mox (2.4%). Over 45% patients did not understand the purpose
of their medications and possible side effects. CONCLUSION:
The LDL goal attainment rate was relatively low in the present
group of patients and there was room for improvement. The
results of the current project paves way for the implementation
of a clinical pharmacy service to assist in hyperlipidaemic man-
agement by providing drug education to patients and suggestions
to physician in lipid lowering drug therapies.
